Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

A long way to the battlefront: CAR T cell therapy against solid cancers.

Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Prospects and challenges for use of CAR T cell therapies in solid tumors

Recent Advances in CAR-Based Solid Tumor Immunotherapy

Engineering Enhanced CAR T-cells for Improved Cancer Therapy.

CAR-T cell therapy: current limitations and potential strategies

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.